Lupin Healthcare

Name

Lupin Healthcare

Legal name

Lupin Healthcare Limited

Website

https://lupinhealthcare.co.uk

Company type

Private

Founded year

1968

Operating status

Operating

Headcount range

11–50 employees

Short description

Lupin Healthcare Limited is the UK subsidiary of Indian pharmaceutical group Lupin Limited, supplying generic and specialty medicines to the NHS across respiratory, neuroscience, HIV, and contraceptive therapeutic areas, with a stated strategic pivot toward complex generics and biosimilars.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (42345)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industry

Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)

Keywords

• Generic pharmaceuticals
• Respiratory medicines
• HIV antiretrovirals
• Specialty medicines
• NHS supply

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Revenue model

1. Generic Pharmaceuticals: Sale of generic medicines including HIV antiretrovirals, oral contraceptives, and standard generics to NHS hospitals and pharmacies in the UK
2. Specialty Pharmaceuticals: Sale of branded specialty medicines in respiratory (Luforbec pMDI) and neuroscience (Namuscla for rare neurological conditions) segments to NHS and healthcare providers
3. Complex Generics and Biosimilars: Future focus on more complex generics and biosimilars as part of portfolio transition from standard generics to specialist organization

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Lupin Healthcare Limited is the UK subsidiary of Lupin Limited (India), focused on supplying generic and specialty prescription medicines to the National Health Service (NHS). The company develops, manufactures, and distributes pharmaceuticals across therapeutic areas including respiratory care, neurology, HIV, and women's health, delivering products through pharmaceutical wholesalers to NHS trusts, hospitals, pharmacies, and clinicians.

Product overview

Lupin Healthcare UK operates as a subsidiary of global pharmaceutical company Lupin Limited, offering a diversified portfolio of generic and specialty medicines focused on three key therapeutic areas: Respiratory (Luforbec pMDI inhalers), HIV anti-retrovirals (Emtricitabine/Tenofovir, Raltegravir), and Neurology (Namuscla, Memantine, Sertraline, Syonell). The company provides affordable quality generics including Lansoprazole, Maexeni oral contraceptive, and Ziclaseg diabetes medication. Lupin Neuroscience is a specialty pharma division dedicated to neurological disorders. Luforbec 100/6 and 200/6 pMDI are carbon-neutral certified respiratory products delivered via pressurised metered dose inhalers.

Differentiator

Problem solved

Functional benefit

Brands

• Luforbec: Respiratory product - beclometasone/formoterol pMDI inhaler for asthma and COPD management
• Luforbec Carbon Neutral
• Lupin Neuroscience

Products and services

• Luforbec
• Namuscla
• HIV Antiretroviral Portfolio
• Oral Contraceptives

Quantifiable outcome

• £93.3 million per year potential cost savings for UK NHS through Luforbec prescribing
• +3 more outcomes

Named customers1 record

Segments4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and flagship.

• RenasciencecoreStrategic or Co-development Partner · 1 April 2025Lupin announced the acquisition of Renascience in the United Kingdom in April 2025, expanding UK portfolio and capabilities.
• Alloga UK LimitedcoreChannel Partner/ Reseller/ DistributorLupin Healthcare (UK) has outsourced and partnered with Alloga UK Limited for purchase order placement and distribution of goods. Alloga UK Limited handles logistics from their warehouse in South Normanton, Derbyshire with general lead time of 24-48 hours from order placement to delivery.
• NHS EnglandcoreStrategic or Co-development PartnerCommitted partner to the NHS. Completed NHS Evergreen Sustainable Supplier Assessment which supports alignment with NHS sustainability priorities. Committed to NHS Net Zero Supplier Roadmap. Collaborates with NHS on joint working projects for patient-centred initiatives.
• NICE (National Institute for Health and Care Excellence)coreStrategic or Co-development PartnerWorks with NICE and regulatory authorities to ensure medicines are brought to patients as quickly as possible.
• Carbon Footprint LtdcoreTechnology or IntegrationConducted Green House Gas assessment and Life Cycle Assessments for respiratory portfolio. Certified all respiratory products as carbon neutral. Supporting development of Carbon Reduction Plan and net zero pathway.
• AbbVieflagshipStrategic or Co-development PartnerPartnering with AbbVie in novel drug development in oncology, immunology and metabolic disorders as part of Lupin's innovation-led transnational pharmaceutical organisation strategy.
• Boehringer IngelheimflagshipStrategic or Co-development PartnerPartnering with Boehringer in novel drug development in oncology, immunology and metabolic disorders as part of Lupin's innovation-led transnational pharmaceutical organisation strategy.
• Association of the British Pharmaceutical Industry (ABPI)coreOthersLupin is committed to working in an open and transparent way in collaboration with ABPI to set high standards of ethical interaction between Lupin and patient organisations and healthcare professionals within the UK. Adheres to ABPI code of practice and discloses payments on Disclosure UK database.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Glenmark Pharmaceuticals: Indian pharma company with growing specialty franchise in respiratory, dermatology, and oncology. Comparable transition strategy from pure generics to specialty, with similar R&D partnerships approach.

Direct peers

• Sun Pharmaceutical Industries: India's largest pharmaceutical company with specialty and generics portfolio. Comparable business model to Lupin with global footprint and specialty franchise in neurology and respiratory segments.
• Aspen Pharmacare: South African-headquartered pharmaceutical company with significant UK operations through Aspen Pharma. Comparable specialty/generics mix with NHS relationships and respiratory/thrombosis portfolio.
• Hikma Pharmaceuticals: UK-headquartered global pharmaceutical company with a comparable mix of generic and specialty products sold through NHS and other healthcare systems. Operates branded and generics across respiratory, oncology, and injectables, similar to Lupin Healthcare's portfolio.
• Aurobindo Pharma: Indian-headquartered global generics manufacturer with significant UK and EU market presence. Direct competitor in HIV antiretrovirals, oral contraceptives, and complex generics distributed to NHS.
• Dr. Reddy's Laboratories: Indian pharmaceutical company with comparable generics and specialty portfolio. Direct competition in UK/EU markets across multiple therapeutic areas including neurology and HIV.
• Cipla: Indian pharmaceutical peer with similar respiratory franchise strength (particularly in pMDIs and inhaled medicines). Competes with Lupin in HIV antiretrovirals, respiratory, and emerging markets specialty categories.

Broad incumbents

• Viatris: Global pharmaceutical company formed from Mylan and Upjohn, offering a broad generics and specialty portfolio. Comparable in scale and product breadth, with significant presence in respiratory and complex generics sold via NHS contracts.
• Sandoz (Novartis): Global leader in generics and biosimilars, spun off from Novartis. Competes with Lupin across generic pharmaceuticals and increasingly in specialty/biosimilars, including respiratory and complex injectables.
• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with a substantial specialty pharma franchise including respiratory products. Direct competitor to Lupin's Luforbec in the ICS/LABA pMDI category globally.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/lupin-healthcare

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lupin Healthcare